Bike in Cyprus

Hong Kong (PRWEB) September 15, 2011

This Marketsensus report provides complete overview on the China pharmaceutical Market

The Chinese hospital prescription pharma market generated sales of $ 22.9 billion in 2009, with an annual growth rate of 26.5% between 2008 and 2009. Key growth drivers include Chinas support of foreign direct investment, low operating costs, growing economic wealth and a government stimulus of $ 125 billion to be spent on healthcare reforms during 20092011.

Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position in China

Assesses the size of the Chinese pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

Examines the Chinese generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

Report Highlights

The combination of Chinas rising population to 2030, plus the expansion of the elderly population, as a proportion of the total population, will create additional pressure on the government in terms of healthcare provision especially for the elderly.

According to the Ministry of Health, by the end of October 2010, the three public health insurance schemes covered 1,233 million Chinese citizens, accounting for more than 90% of the total population.

Domestic manufacturers dominate the Chinese generics market, accounting for nearly 99% of generics sales of both branded and unbranded generics. The domestic industry has expanded rapidly as companies have improved their manufacturing capacities.

Reasons to Purchase

Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in China

Quantify the size and growth of the prescription pharmaceutical market in China, analyzing key therapy areas, brands and companies

Assess drivers and resistors of generic and biosimilars uptake in China

About the Strategic Pharmaceutical Analysis Team 2

Geographic specific reports: 2

Global issue reports: 2

Executive Summary 3

Introduction 3

Strategic scoping and focus 4

Key findings – Healthcare drivers and resistors in China 5

China – Socio-demographic and economic analysis 8

Socio-demographic trends 8

Socio-economic trends 9

China – Healthcare system and drug regulatory analysis 11

Healthcare expenditure 11

Healthcare system 12

Healthcare insurance 12

Regulatory issues 12

Pricing and reimbursement issues 13

China – Prescription pharmaceutical sales analysis 15

Pharmaceutical market size 15

Leading therapy areas 15

Leading prescription pharmaceutical brands 15

Leading pharmaceutical companies 15

China – Drug expiry analysis 17

China generics market 17

China brand erosion post patent expiry 17

China biosimilars market 17

China – Pharmaceutical Industry Infrastructure analysis 19

Related reports 21

Upcoming related reports 21

Table of Contents 22

2. China – Socio-demographic and economic analysis 23

China – Key findings 23

Socio-demographic trends 23

Socio-economic trends 23

China – Demographic trends 25

Chinese population growth rate expected to slow 25

Birth rate in China is declining 28

Proportion of elderly people in the China expected to rise 29

Life expectancy will continue to increase in China and across other markets 30

China – Disease burden 31

No longer Kingdom of Bicycles, but still Kingdom of Cigarettes 33

Demographic changes lead to increase in more Westernized chronic conditions 33

Tuberculosis prevalence is high but is declining 34

Hepatitis incidence increasing despite universal vaccination coverage 34

China – Regional score card analysis 36

Mainland China is divided into 31 administrative regions (22 provinces, 5 autonomous regions, and 4 municipality cities) 37

Total healthcare scores of different regions in China 38

The eastern coastal provinces are more densely populated than the western interior 39

Disparity of economic development directly impacts the healthcare expenditure 40

Most hospitals are situated in big cities in China 45

Lifeexpectancy is higher in the eastern coastal provinces 51

China – Political climate 52

Overview of Chinese governmental departments and healthcare reform policies 52

China – Economic climate 55

Government’s stimulus plan compensates for the global recession 55

Pharma has historically been relatively well insulated from the recession 58

China – Business environment 59

Factors responsible for driving China’s strong GDP growth 59

Foreign direct investment is contributing to economic growth 59

Low cost manufacturing drivers exports 60

Taxation system in China – complex but R&D tax credits exist 61

Corruption remains widespread 61

Cultural differences and the language barrier can impact business with Western companies 62

China’s unemployment rate – official versus unofficial reports 62

Renminbi (RMB) appreciation and its impact on the pharmaceutical industry 63

3. China – Healthcare system and drug regulatory analysis 66

China – Key findings 66

Healthcare expenditure 66

Healthcare system 66

Healthcare insurance 66

Regulatory issues 67

Pricing and reimbursement issues 67

China – Healthcare expenditure 69

China – Healthcare system 71

Regulatory healthcare bodies 71

Ministry of Health sets the high-level policies 72

Ministry of Human Resources and Social Security oversees the national medical insurance system 72

The National Council for Social Security Fund is often surrounded by scandals 72

China Insurance Regulatory Commission regulates private insurance sector 72

National Development and Reform Commission oversees overall policy development 72

State Administration for Industry and Commerce 73

China’s healthcare reform 73

China healthcare reform, 2010-2020 The Glorious Ten? 75

China – Health insurance 77

China – Social health insurance 78

The introduction of the urban employee Basic Medical Insurance System has improved health insurance coverage in cities 79

The unemployed are offered a very basic health insurance 80

Rural health insurance coverage is increasing but the benefits are insufficient 80

China – Private health insurance 82

Primary versus secondary care 83

China – Regulatory issues 84

State Food and Drug Administration is the watchdog for drug registration and safety issues 84

Evolution of the SFDA 85

Drug classification in China 87

Drug Monitoring Period 87

Drug registration in China 87

New Provisions for Drug Registration led to a fall in drug approvals 91

New pathway for expedited drug approval 91

GMP regulation in China 92

Intellectual property protection 93

State Intellectual Property Office (SIPO) 93

China provides 6 years of data exclusivity for pharmaceuticals, but it is not applied adequately in practice